Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20614505 | 1.00 | CYP1A2 (0.59) | CYP1A2TDP1SMN1; SMN2KDM4EPIK3CD | |
| SCHEMBL23011655 | 0.93 | CYP1A2 (0.52) | CYP1A2TDP1SMN1; SMN2KDM4EPIK3CD | |
| SCHEMBL572569 | 0.85 | ALDH1A1 (0.45) | CYP1A2TDP1KDM4EALDH1A1KMT2A | |
| SCHEMBL860793 | 0.85 | CYP1A2 (0.77) | CYP1A2TDP1SMN1; SMN2KDM4EPIK3CD | |
| SCHEMBL14407779 | 0.85 | CYP1A2 (0.77) | CYP1A2TDP1SMN1; SMN2KDM4EPIK3CD | |
| SCHEMBL37407 | 0.85 | — | — | |
| SCHEMBL422638 | 0.85 | — | — | |
| SCHEMBL21056389 | 0.82 | ACACB (0.44) | CYP1A2TDP1EPHX2 | |
| SCHEMBL5430146 | 0.79 | CYP1A2 (0.54) | CYP1A2TDP1SMN1; SMN2KDM4EPIK3CD | |
| SCHEMBL3249258 | 0.79 | CYP1A2 (0.54) | CYP1A2TDP1SMN1; SMN2KDM4EPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | claimed |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2019-07-11 | — | — | US | claimed |
| EP-3498716-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | Hongyun Biotech Co., Ltd. (CN) | 2019-06-19 | — | — | EP | claimed |
| CN-109575045-A | Thienopyrimidines, preparation method, Pharmaceutical composition and its application | 南京红云生物科技有限公司 | 2019-04-05 | — | — | CN | claimed |
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | claimed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | claimed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | claimed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | claimed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | claimed |
| US-7166599-B2 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-23 | — | — | US | claimed |
| US-20050090486-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-04-28 | — | — | US | claimed |
| US-20030134838-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-17 | — | — | US | claimed |
| EP-0824544-B1 | PEPTIDYL COMPOUNDS WHICH INHIBIT METALLOPROTEINASE AND TNF LIBERATION AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2003-04-16 | — | — | EP | claimed |
| US-6214604-B1 | PURE CULTURE OF BURKHOLDERIA STRAIN DSM 9925 | LONZA AG (CH) | 2001-04-10 | — | — | US | claimed |
| EP-3793565-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | Hongyun Biotech Co., Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| CN-109575045-B | Thienopyrimidine compound, preparation method thereof, medicinal composition and application thereof | 南京红云生物科技有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-6214604-B1 | PURE CULTURE OF BURKHOLDERIA STRAIN DSM 9925 | LONZA AG (CH) | 2001-04-10 | — | — | US | disclosed |
| CN-1273582-A | New process for producing aminoperazine derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-11-15 | — | — | CN | disclosed |
| EP-1043320-A1 | NEW PROCESS FOR PRODUCING AMINOPIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134838-A1 | Trisubstituted pyrimidines | APP, PSEN1, BACE1 | CYP1A2 409/4885TDP1 17/4885SMN1; SMN2 131/4885 |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | CYP1A2 331/4885TDP1 1722/4885SMN1; SMN2 4832/4885 |
| US-20050090486-A1 | Trisubstituted pyrimidines | APP, BACE1, PSEN1 | CYP1A2 290/4885TDP1 38/4885SMN1; SMN2 178/4885 |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | CYP1A2 1209/4885TDP1 1408/4885SMN1; SMN2 3893/4885 |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | CYP1A2 1209/4885TDP1 1408/4885SMN1; SMN2 3893/4885 |
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | ALK, MET, TIE1 | CYP1A2 1209/4885TDP1 1408/4885SMN1; SMN2 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.